Cloverleaf Bio is a Yale spinout developing a new class of engineered tRNA therapeutics for cancer. Its proprietary “Trojan horse tRNAs” are designed to selectively trap multiple tRNA-modifying enzymes on which tumor cells depend, combining the precision of RNA medicines with a differentiated, multi-target mechanism of action. Backed by a $33 million seed financing from leading life-sciences investors, Cloverleaf is advancing its lead programs in colorectal cancer and hepatocellular carcinoma.